Table 1:
Patient characteristics by neoadjuvant cycles
| Variables | Whole Cohort | 3 Cycles | 4 Cycles | >=5 Cycles | p-value* |
|---|---|---|---|---|---|
| Patients (n) | 199 | 73 | 70 | 56 | |
| Age at Diagnosis | |||||
| Median(Mean) | 66.5(66.5) | 66(66.1) | 65.5(65) | 68.6(68.9) | 0.111 |
| Range | 43.1–87.9 | 43.1–86.4 | 43.2–87.2 | 45.1–87.9 | |
| Histology | |||||
| High Grade Serous | 183(92%) | 65(89%) | 66(94.3%) | 52(92.9%) | 0.516 |
| Others** | 16(8%) | 8(11%) | 4(5.7%) | 4(7.1%) | |
| Stage | |||||
| III | 66(33.2%) | 29(39.7%) | 23(32.9%) | 14(25%) | 0.226 |
| IV | 133(66.8%) | 44(60.3%) | 47(67.1%) | 42(75%) | |
| BRCA Status | |||||
| No mutation | 139(69.8%) | 48(65.8%) | 49(70%) | 42(75%) | 0.344 |
| BRCA1/2 Mutation | 30(15.1%) | 14(19.2%) | 12(17.1%) | 4(7.1%) | |
| Not tested | 30(15.1%) | 11(15.1%) | 9(12.9%) | 10(17.9%) | |
| Charlson score (12 missing) | |||||
| Median (Mean) | 8(8.5) | 8(8.4) | 8(8.4) | 9(8.6) | 0.451 |
| Range | 6–12 | 6–12 | 6–12 | 6–12 | |
| Chemotherapy Regimen (12 missing) | |||||
| Weekly Paclitaxel/Carboplatin | 134(71.7%) | 52(77.6%) | 49(73.1%) | 33(62.3%) | 0.17 |
| Others | 53(28.3%) | 15(22.4%) | 18(26.9%) | 20(37.7%) | |
| Neoadjuvant Indication *** | |||||
| Patient factors | 60(30.2%) | 28(38.4%) | 16(22.9%) | 16(28.6%) | 0.13 |
| Disease factors | 139(69.8%) | 45(61.6%) | 54(77.1%) | 40(71.4%) | |
| Response on Imaging after 2–3 Preoperative Cycles | |||||
| Response | 181(91%) | 68(93.2%) | 66(94.3%) | 47(83.9%) | 0.116 |
| No response/progression | 18(9%) | 5(6.8%) | 4(5.7%) | 9(16.1%) | |
| Optimal Debulking | |||||
| No | 18(9%) | 8(11%) | 5(7.1%) | 5(8.9%) | 0.745 |
| Yes | 181(91%) | 65(89%) | 65(92.9%) | 51(91.1%) | |
| Complete Gross Resection | |||||
| No | 60(30.2%) | 23(31.5%) | 21(30%) | 16(28.6%) | 0.962 |
| Yes | 139(69.8%) | 50(68.5%) | 49(70%) | 40(71.4%) | |
| Adjuvant Therapy (4 missing) | |||||
| No | 15(7.7%) | 1(1.4%) | 3(4.3%) | 11(20%) | <0.001 |
| Yes | 180(92.3%) | 69(98.6%) | 67(95.7%) | 44(80%) | |
| Postoperative Cycles | |||||
| Median (Mean) | 3(2.9) | 3(3.2) | 3(2.8) | 2(2.4) | <0.001 |
| Range | 1–6 | 2–6 | 1–4 | 1–4 | |
*
P-values are obtained using Kruskal-Wallis test for continuous variables and Fisher-Exact test for categorical variables.
**
Of the 16 women with other histologies, 2 had clear cell carcinoma, 1 had endometrioid, 2 had carcinosarcoma, 1 had low grade serous, and 10 had Mullerian carcinoma (non-specific).
***
Patient factors include Aletti Score, comorbidity, venous thromboembolism, clinical trial, or other. Disease factors include Stage IV unresectable, extent of disease on imaging, extent of disease on laparoscopy, extent of disease requiring thoracic surgery.